ANZEMET INJECTION Rx
Generic Name and Formulations:
Dolasetron mesylate 20mg/mL; IV inj.
Indications for ANZEMET INJECTION:
Prevention and treatment of post-op nausea & vomiting.
Give by IV inj, either undiluted 100mg over 30 seconds or diluted to 50mL and infused over up to 15 mins. ≥16yrs: Prevention: 12.5mg given as a single dose about 15 mins before stopping anesthesia. Treatment: 12.5mg as soon as needed.
May give by IV inj as in adult dose, or may be mixed into apple or apple-grape juice and taken orally (timing and doses are different; see full labeling). <2yrs: not established. 2–16yrs: Prevention: 0.35mg/kg IV (max 12.5mg) given as single dose about 15 mins before stopping anesthesia; or, 1.2mg/kg (max 100mg) mixed into apple or apple-grape juice and taken orally within 2hrs before surgery. Treatment: 0.35mg/kg IV as soon as needed.
Inj soln administered by IV: Prevention of nausea & vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses in adults and children.
Increased risk of developing QTc, PR and QRS interval prolongation. Avoid in patients with congenital QT syndrome, hypokalemia, hypomagnesemia, complete heart block or risk of (unless paced). Correct electrolyte imbalances prior to therapy. Monitor ECG periodically. CHF. Bradycardia. Pre-existing conduction abnormalities and underlying structural heart disease. Sick sinus syndrome. Atrial fibrillation with slow ventricular response. Recent MI. Renal impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.
Selective 5-HT3 receptor antagonist.
Caution with drugs which can prolong ECG intervals (eg, verapamil, flecainide, quinidine), diuretics, and with cumulative high-dose anthracycline therapy. Serotonin syndrome possible with concomitant serotonergic drugs (eg, SSRIs, SNRIs). Potentiated by cimetidine, atenolol (IV dolasetron). Antagonized by rifampin.
Headache, dizziness, pain, fatigue, diarrhea, bradycardia, tachycardia, dyspepsia, chills/shivers, ECG changes, 2nd or 3rd-degree AV block; serotonin syndrome (discontinue if occurs).
Tabs—5; Single-use vials (100mg/5mL)—1; Single-use vials (12.5mg/0.625mL)—6; Multidose vial (500mg/25mL)—1
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)